Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.
- Record $23.9m sales revenue, up 30% year-on-year
- Same-store sales surged 39%, outpacing category growth
- Onshore manufacturing deal with Specialty Probiotics Australia
- International sales rose 26%, expanding in Canada, UK, Ireland, NZ
- On track for Vision 27 cumulative $75m sales target
Record Sales Growth Amid Consumer Health Challenges
Biome Australia Limited (ASX:BIO) has delivered a standout FY26 performance, with preliminary unaudited sales revenue hitting $23.9 million; a 30% lift on FY25 and a new company record. This growth stands out in a tough consumer health environment, underscoring Biome’s ability to outpace category trends and capture market share.
Same-store sales across all channels jumped 39%, dwarfing the broader probiotics category growth of around 6%. June marked a milestone with estimated sell-through surpassing 100,000 monthly units for the first time, driven largely by Biome Daily becoming the leading probiotic product by units sold in Australian community pharmacies.
New Revenue Streams and Half-Year Momentum
Biome added $5.5 million of new sales revenue in FY26; exceeding its entire revenue from FY22; highlighting strong scaling momentum. The second half of FY26 generated $11.5 million, a 20% increase on the prior corresponding period and the company’s second-largest half-year result on record.
Over the past six years, Biome has compounded sales revenue at approximately 60% annually since FY21, accelerating from about 74% per annum since FY20. This sustained growth trajectory reflects robust demand and effective execution.
Onshore Manufacturing to Unlock Margin and Working Capital Benefits
In a strategic supply chain move, Biome inked a binding agreement in June 2026 with Specialty Probiotics Australia to manufacture its Activated Probiotics range domestically. This first phase of the Vision 27 plan requires no upfront capital and aims for the first commercial batch by September 2026.
Bringing production onshore is expected to deliver multiple benefits: an Australian-made advantage in export markets, improved gross margins, and significant working capital efficiencies through lower inventory and faster stock turnover. This shift also eliminates extended international sea freight, potentially freeing cash for reinvestment in growth initiatives.
International Expansion on a Capital-Light Model
Biome’s international sales revenue rose 26% to $1.8 million, with established footholds in Canada, Ireland, the United Kingdom, and New Zealand. The company’s lean approach avoids costly local operations by deploying satellite sales and education teams reporting into Australia, which keeps overheads low and growth nimble.
In Canada, partnerships with Fullscript and Ecotrend Ecologics, alongside provincial territory managers, have laid a foundation for scaling. In Ireland, Biome launched via Uniphar’s pharmacy network; in the UK, it supplies health food and pharmacy channels directly; and in New Zealand, it partnered with the ProPharma group. With onshore manufacturing enabling smaller batch runs tailored to these markets, Biome anticipates materially stronger international growth in FY27.
Vision 27 Target Within Reach
Biome remains on track to meet its Vision 27 goal of at least $75 million cumulative sales over FY25 to FY27, having delivered $42.3 million in the first two years. The plan anticipates a revenue step-up in FY27 driven by international scaling, supply chain efficiencies from onshore manufacturing, ongoing Australian market momentum, and a pipeline of new product launches and growth initiatives yet to be detailed.
Managing Director Blair Vega Norfolk highlighted the company’s confidence: “FY26 was a record year, with sales up 30% to $23.9 million and demand stronger than ever. We’ve spent two years building for this, and FY27 is set to be our biggest year yet for scale.”
Bottom Line?
Biome’s FY26 results and strategic onshore manufacturing move position it well for accelerated international growth and margin expansion in FY27.
Questions in the middle?
- How quickly will onshore manufacturing translate into improved margins and working capital?
- What specific new products and growth initiatives will Biome launch to sustain momentum?
- Can Biome’s capital-light international model scale effectively amid competitive global probiotic markets?